PharmAbcine Balance Sheet Health
Financial Health criteria checks 5/6
PharmAbcine has a total shareholder equity of ₩16.6B and total debt of ₩4.8B, which brings its debt-to-equity ratio to 29%. Its total assets and total liabilities are ₩26.7B and ₩10.1B respectively.
Key information
29.0%
Debt to equity ratio
₩4.81b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩18.96b |
| Equity | ₩16.58b |
| Total liabilities | ₩10.11b |
| Total assets | ₩26.70b |
Financial Position Analysis
Short Term Liabilities: A208340's short term assets (₩20.5B) exceed its short term liabilities (₩7.1B).
Long Term Liabilities: A208340's short term assets (₩20.5B) exceed its long term liabilities (₩3.0B).
Debt to Equity History and Analysis
Debt Level: A208340 has more cash than its total debt.
Reducing Debt: A208340's debt to equity ratio has increased from 1.3% to 29% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A208340 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A208340 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.1% each year.